Natural history and outcomes in localised immunoglobulin light-chain amyloidosis: a long-term observational study
Shameem Mahmood(The Royal Free Hospital), Ashutosh Wechalekar(University College Hospital), Helen J. Lachmann(Royal Free London NHS Foundation Trust), Philip N. Hawkins(The Royal Free Hospital), Janet A. Gilbertson(The Royal Free Hospital), Marianna Fontana(Amyloidosis Foundation), Julian D. Gillmore(Alnylam Pharmaceuticals (United States)), Carol Whelan(The Royal Free Hospital), Thomas Wagner(The Royal Free Hospital), Sajitha Sachchithanantham(The Royal Free Hospital), Frank Bridoux(Université de Poitiers), Ketna Patel(National Institutes of Health), Christopher P. Venner(BC Cancer Agency), Rabya Sayed(National Institutes of Health), Dorota Rowczenio(Children's Cancer and Leukaemia Group)
Cited by 153
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
NALP3 Forms an IL-1β-Processing Inflammasome with Increased Activity in Muckle-Wells Autoinflammatory Disorder
|Immunity|2004|1.7k
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
|New England Journal of Medicine|2021|1.7k